We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

An Observational Study on Patients With Non-Squamous NSCLC Who Reached A Long PFS After Avastin (Bevacizumab)-Based First-Line Therapy

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01343914
First Posted: April 28, 2011
Last Update Posted: November 2, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Hoffmann-La Roche
  Purpose
This retrospective observational study will analyse demographic, clinical and treatment-related data of patients with non-squamous non-small cell lung cancer (NSCLC) who had reached >/= 9 months of progression-free survival after Avastin (bevacizumab)-based first-line therapy. Data will be collected for approximately 9 months.

Condition
Non-Squamous Non-Small Cell Lung Cancer

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Retrospective Study to Determinate the Clinical Phenotype of Patients With Non Squamous NSCLC Treated With First Line Bevacizumab-based Therapy That Reached a Long PFS

Resource links provided by NLM:


Further study details as provided by Hoffmann-La Roche:

Primary Outcome Measures:
  • Progression-free survival (>9 months) according to clinical phenotype [ Time Frame: approximately 9 months ]

Secondary Outcome Measures:
  • Overall survival [ Time Frame: approximately 9 months ]
  • Safety: Incidence of adverse events [ Time Frame: approximately 9 months ]

Enrollment: 118
Study Start Date: June 2011
Study Completion Date: December 2011
Primary Completion Date: December 2011 (Final data collection date for primary outcome measure)

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Non squamous NSCLC patients treated with bevacizumab-based first line therapy and PFS >/= 9 months
Criteria

Inclusion Criteria:

  • Adult patients, >/= 18 years of age
  • Non-squamous non-small cell lung cancer (NSCLC) treated with first-line Avastin-based therapy
  • Progression-free survival of >/= 9 months reached

Exclusion Criteria:

  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01343914


Locations
Spain
Alcoy, Alicante, Spain, 03804
Elche, Alicante, Spain, 03203
Elda, Alicante, Spain, 03600
Almería, Almeria, Spain, 04009
San Sebastian de Los Reyes, Guipuzcoa, Spain, 28702
Manacor, Islas Baleares, Spain, 07500
Palma de Mallorca, Islas Baleares, Spain, 07012
Santiago de Compostela, La Coruña, Spain, 15706
Vigo, Pontevedra, Spain, 36312
Alicante, Spain, 3010
Barcelona, Spain, 08028
Barcelona, Spain, 08041
Barcelona, Spain, 08916
Caceres, Spain, 10003
Jaen, Spain, 23007
Leon, Spain, 24071
Lugo, Spain, 27004
Madrid, Spain, 28007
Madrid, Spain, 28033
Madrid, Spain, 28034
Madrid, Spain, 28040
Madrid, Spain, 28046
Madrid, Spain, 28050
Madrid, Spain, 28935
Malaga, Spain, 29010
Murcia, Spain, 30008
Navarra, Spain, 31008
Pontevedra, Spain, 36002
Sevilla, Spain, 41013
Valencia, Spain, 46015
Valencia, Spain, 46017
Valencia, Spain, 46026
Zaragoza, Spain, 50009
Sponsors and Collaborators
Hoffmann-La Roche
Investigators
Study Director: Clinical Trials Hoffmann-La Roche
  More Information

Responsible Party: Hoffmann-La Roche
ClinicalTrials.gov Identifier: NCT01343914     History of Changes
Other Study ID Numbers: ML25494
First Submitted: April 12, 2011
First Posted: April 28, 2011
Last Update Posted: November 2, 2016
Last Verified: November 2016

Additional relevant MeSH terms:
Carcinoma, Non-Small-Cell Lung
Carcinoma, Bronchogenic
Bronchial Neoplasms
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Bevacizumab
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Antineoplastic Agents